Zobrazeno 1 - 10
of 10
pro vyhledávání: '"G Weldon Gilcrease"'
Autor:
David D Stenehjem, Courtney C Cavalieri, Eric Swanson, Benjamin Solomon, Jonathan Whisenant, Dao Tran, John Weis, G Weldon Gilcrease, Sunil Sharma, Ignacio Garrido-Laguna
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Pp 1-6 (2018)
Background: Tumors with deficient mismatch repair (dMMR) have a favorable immunological phenotype permitting exploitation by immunotherapies. We aimed to assess our institutional experience of dMMR advanced gastrointestinal (GI) cancers treated with
Externí odkaz:
https://doaj.org/article/518196c78f6e47e7b0d8093b057286ec
Autor:
Jack Skinner, Daniel B Martin, Peter D. Stetson, G. Weldon Gilcrease, Jessica Sugalski, Mia Levy, Robert C. Stillman
Publikováno v:
JCO oncology practice. 18(1)
PURPOSE: Clinical notes function as the de facto handoff between providers and assume great importance during unplanned medical encounters. An organized and thorough oncology history is essential in care coordination. We sought to understand reader p
Autor:
Mona Foth, Courtney C. Cavalieri, Lance D. Burrell, Stephanie L. Cutler, Conan G. Kinsey, Kajsa E. Affolter, Jill E. Shea, Amelie M. Boespflug, Kaitrin M. Rehbein, Alana L. Welm, Jeffrey T. Yap, Bryan E. Welm, Michael T. Seipp, Sophia S. Schuman, Jonathan Whisenant, G. Weldon Gilcrease, Amanda Truong, David H. Lum, Katrin P. Guillen, Courtney L. Scaife, Martin McMahon, Eric L. Snyder, Soledad A. Camolotto
Publikováno v:
Nature medicine
Pancreatic ductal adenocarcinoma (PDA) was responsible for ~ 44,000 deaths in the United States in 2018 and is the epitome of a recalcitrant cancer driven by a pharmacologically intractable oncoprotein, KRAS1–4. Downstream of KRAS, the RAF→MEK→
Autor:
G. Weldon Gilcrease, Kelli M. Thorne, David D. Stenehjem, Mark Wade, Kimberly McGregor, Sunil Sharma, Ignacio Garrido-Laguna, Jonathan Whisenant, Kenneth M. Boucher, Nicole Orgain, John R. Weis
Publikováno v:
Investigational New Drugs. 37:482-489
Background This phase I/II trial evaluated toxicity and antitumor activity of everolimus plus mFOLFOX6 + bevacizumab for first-line treatment of metastatic colorectal cancer (mCRC). Methods A phase I, modified 3 + 3 Fibonacci schema determined the ma
Autor:
Benjamin Solomon, Jonathan Whisenant, Courtney C. Cavalieri, G. Weldon Gilcrease, Ignacio Garrido-Laguna, David D. Stenehjem, John R. Weis, Sunil Sharma, Dao Tran, Eric R. Swanson
Publikováno v:
Journal of Immunotherapy and Precision Oncology. 1:1-6
Background: Tumors with deficient mismatch repair (dMMR) have a favorable immunological phenotype permitting exploitation by immunotherapies. We aimed to assess our institutional experience of dMMR advanced gastrointestinal (GI) cancers treated with
Autor:
Weining Zhen, Leonard B. Saltz, Marvaretta Stevenson, G. Weldon Gilcrease, Mary Anne Bergman, Renato Lenzi, Asif Rashid, Charles R. Handorf, Gauri R. Varadhachary, Keith D. Eaton, Justin M M Cates, Richard Schwab, Lawrence N. Shulman, John E. Phay, Mihaela C. Cristea, Daniel W. Bowles, Efrat Dotan, David S. Ettinger, David S. Gierada, Panagiotis Fidias, Renuka Iyer, Deborah A. Freedman-Cass, Jonathan S. Zager, Mark Agulnik, Kelly N. Godby, Jeffrey B. Smerage
Publikováno v:
Journal of the National Comprehensive Cancer Network. 12:969-974
The NCCN Guidelines for Occult Primary tumors provide recommendations for the evaluation, workup, management, and follow-up of patients with occult primary tumors (cancers of unknown primary). These NCCN Guidelines Insights summarize major discussion
Autor:
Courtney C. Cavalieri, Katrin P. Guillen, Courtney L. Scaife, Kajsa E. Affolter, Lance D. Burrell, Jill E. Shea, Sophia S. Schuman, Alana L. Welm, Martin McMahon, David H. Lum, Jonathan Whisenant, Amanda Truong, Soledad A. Camolotto, Mona Foth, Conan G. Kinsey, Eric L. Snyder, Stephanie L. Cutler, G. Weldon Gilcrease, Amelie M. Boespflug, Kaitrin M. Rehbein, Jeffrey T. Yap, Michael T. Seipp, Bryan E. Welm
Publikováno v:
Cancer Research. 79:2183-2183
Pancreatic ductal adenocarcinoma was responsible for ~43,000 deaths in the USA in 2017 and is the epitome of a recalcitrant cancer driven by an, as yet, pharmacologically intractable oncoprotein, KRAS. Although the clinical picture remains grim, the
Autor:
Kaitrin M. Rehbein, Mona Foth, Courtney C. Cavalieri, Stephanie L. Cutler, Sophia S. Schuman, Michael T. Seipp, Lance D. Burrell, Jill E. Shea, Alana L. Welm, Conan G. Kinsey, David H. Lum, Amelie M. Boespflug, G. Weldon Gilcrease, Jonathan Whisenant, Kajsa E. Affolter, Amanda Truong, Eric L. Snyder, Soledad A. Camolotto, Jeffrey T. Yap, Katrin P. Guillen, Courtney L. Scaife, Martin McMahon, Bryan E. Welm
Publikováno v:
Nature Medicine. 25:861-861
In the version of this article initially published, the label over the bottom schematic in Fig. 1a was “pH > 5.0”; it should have been “pH < 5.0”. Further, the original article misspelt the surname of Katrin P. Guillen as “Gullien”. These
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.